9.46
+0.23(+2.49%)
Currency In USD
| Previous Close | 9.23 |
| Open | 9.1 |
| Day High | 9.62 |
| Day Low | 9.1 |
| 52-Week High | 896 |
| 52-Week Low | 6.71 |
| Volume | 89,249 |
| Average Volume | 1.18M |
| Market Cap | 4.88M |
| PE | -0.01 |
| EPS | -639.11 |
| Moving Average 50 Days | 11.93 |
| Moving Average 200 Days | 101.75 |
| Change | 0.23 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $0.48 as of July 03, 2025 at a share price of $9.46. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $0.47 as of July 03, 2025 at a share price of $9.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
GlobeNewswire Inc.
Jun 23, 2025 12:15 PM GMT
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L wi
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
Jun 17, 2025 12:15 PM GMT
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutic
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
GlobeNewswire Inc.
Jun 06, 2025 12:15 PM GMT
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagoc